Fox Chase Cancer Center Joins Onclive In Strategic Alliance Partnership Program

OncLive

PLAINSBORO, NJ (February 4, 2015) – OncLive® and Fox Chase Cancer Center – a National Cancer Institute (NCI)-designated Comprehensive Cancer Center that is part of the Temple University Health System in Philadelphia – announced today that they have joined forces to raise awareness of significant oncology research and clinical practice news through OncLive’s Strategic Alliance Partnership program. Through the new partnership, OncLive’s editorial and marketing teams will work with Fox Chase Cancer Center to highlight important oncology research and clinical practice news from the Center.

“We are honored to partner with Fox Chase Cancer Center to increase awareness of the Center’s cutting-edge work on cancer,” says Mike J. Hennessy Jr., Senior Vice President, Oncology & Specialty Pharmacy. “The more we get the word out about new developments in cancer care, the more likely we are to keep finding better ways to treat, prevent or even cure this disease.”

Fox Chase’s rank as an NCI-designated Comprehensive Cancer Center makes it one of only 41 centers in the country to hold this highest level of designation. The doctors at Fox Chase treat more cases of rare and common cancers than other hospitals – and research shows that more experience is linked to better outcomes. In addition, Fox Chase physicians and researchers are leaders in setting new guidelines for breakthrough medicine and comprehensive care.

“Fox Chase is committed to pioneering discoveries that advance new approaches to cancer treatment, prevention, detection and survivorship,” said Richard I. Fisher, MD, President and CEO of Fox Chase. “We look forward to working with OncLive to share new developments at Fox Chase with the healthcare professional and patient communities.”

The strategic alliance will offer healthcare professionals and patients direct, timely access to key developments in cancer treatment and research happening at Fox Chase and more than 30 other leading cancer centers, nursing schools, and physician groups around the country via OncLive’s publications.

About OncLive®


OncLive.com is the official website for Intellisphere’s Oncology Specialty Group, which publishes Oncology & Biotech News, OncologyLive, Oncology Nursing News, and Contemporary Oncology. OncLive® offers oncology professionals with resources and information to provide the best care for their patients. Intellisphere, LLC, a leading provider of health care publishing, research, and education, is part of the Michael J. Hennessy Associates, Inc. (MJH) family of businesses, based in Plainsboro, NJ. MJH also includes the acclaimed CURE Media Group, which combines science and humanity to make cancer understandable. Its flagship product is CURE magazine, the largest consumer publication in the U.S. focused entirely on cancer, reaching cancer patients, cancer centers, and advocacy groups. To learn more, please visit www.OncLive.com. 

Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence six consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

For more information, call 888-369-2427

Resize Text

Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence six consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

For more information, call 888-369-2427